In a report by the Gesundheit Österreich GmbH / Österreichisches Bundesinstitut für Gesundheitswesen (GÖG/ÖBIG – Austrian Health Institute), measures for promoting the rational use of medicines in the 27 EU Member States were surveyed.
Promoting rational use of medicines in Europe
Home/Reports | Posted 25/03/2011 0 Post your comment
Key measures for the rational use of medicines studied by GÖG/ ÖBIG were:
- International non-proprietary name (INN) prescribing
Physicians prescribing by the active ingredient name (INN) rather than the brand name.
- Prescription guidelines
Prescription guidelines ensure that the right medicine at the correct dose is given to the right patient at the right time.
- Pharmaceutical budgets for doctors
When third party payers (sickness funds or national health services) apply this cost-containment measure, the maximum amount of money to be spent on medicines in a specific region or over a period of time is fixed.
- Generic substitution
When pharmacists substitute a brand name medicine for a generic or another cheaper medicine containing the same active ingredient(s).
- Prescription monitoring
The act of assessing/observing prescribing practices of physicians applied by payers. It is sometimes accompanied by feedback to prescribers.
- Information activities targeted at the general public
Information activities carried out by payers to convey the reasons for rational drug use, e.g. campaigns to promote generics.
In some of the countries surveyed by GÖG/ÖBIG these measures were only indicative, whereas in others they were obligatory, including sanctions for non-compliance in some cases.
The series of seven articles that follow present the results obtained by the GÖG/ÖBIG study.
Acknowledgement
This article is published with permission of the Gesundheit Österreich GmbH (GÖG)/Austrian Health Institute.
We gratefully acknowledge the support from Dr Sabine Vogler of Gesundheit Österreich GmbH / Österreichisches Bundesinstitut für Gesundheitswesen (GÖG/ÖBIG – Austrian Health Institute) to GaBI Online.
Related articles
The EU and rational use of medicines
Survey on rational use of medicines in 27 EU Members States
The Netherlands and rational use of medicines
Italy’s rational use of medicines
Germany’s rational use of medicines
Rational use of medicines in Denmark
France’s rational use of medicines
Reference
Vogler S, Schmickl B. Rational use of medicines in Europe. Gesundheit Österreich GmbH / Österreichisches Bundesinstitut für Gesundheitswesen (GÖG/ÖBIG). February 2010.
Guidelines
Regulatory update for post-registration of biological products in Brazil
New regulations in Brazil for the registration of biosimilars
Policies & Legislation
NPRA Malaysia trials new timelines for variation applications
Regulatory evolution and impact of simplified requirements for interchangeable biosimilars in the US
Comments (0)
Post your comment